Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gönen, A Gutiérrez, JM Broto… - The lancet …, 2009 - thelancet.com
Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …
被引用次数：613 相关文章

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gönen, A Gutiérrez… - The Lancet …, 2009 - pubmed.ncbi.nlm.nih.gov
Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gönen, A Gutiérrez, JM Broto… - The Lancet …, 2009 - thelancet.com
Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

[引用][C] Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

G JS - Lancet Oncol, 2009 - cir.nii.ac.jp
Development and validation of a prognostic nomogram for recurrence-free survival after
complete surgical resection of localised primary gastrointestinal stromal tumour : a retrospective …

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gönen, A Gutiérrez… - The Lancet …, 2009 - mayoclinic.elsevierpure.com
Background: Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gönen, A Gutiérrez, JM Broto… - The Lancet …, 2009 - europepmc.org
Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gönen, A Gutiérrez, JM Broto… - The Lancet …, 2009 - Elsevier
BACKGROUND: Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gonen, A Gutierrez, JM Broto… - Lancet …, 2009 - repository.cshl.edu
BACKGROUND: Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …
[PDF] academia.edu

[PDF][PDF] Development and Validation of a Prognostic Nomogram for Recurrence-Free Survival after Complete Surgical Resection of Localized, Primary Gastrointestinal …

Lancet Oncol, 2009 - academia.edu
Background—An optimal staging system to estimate the risk of recurrence following the
complete resection of localized, primary gastrointestinal stromal tumor (GIST) has not been …

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …

JS Gold, M Gönen, A Gutiérrez, JM Broto… - The Lancet …, 2009 - infona.pl
Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after resection of
localised primary gastrointestinal stromal tumours (GIST). We aimed to develop a nomogram …